share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 13 16:05
Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, has announced the approval of its voluntary delisting from the Canadian Securities Exchange (CSE). The delisting is set to take effect at the close of trading on March 14, 2024. Clearmind Medicine, which is also listed on the NASDAQ under the symbol CMND, cited the low trading volume on the CSE as the primary reason for the delisting, stating that it no longer justifies the expenses and administrative efforts of maintaining a dual listing. The company expects that centralizing its marketplace on the NASDAQ will benefit long-term liquidity and shareholder value. Clearmind assured that its Canadian shareholders would still be able to trade shares through brokers on the NASDAQ, as many Canadian brokers have the capability to trade NASDAQ-listed securities. The company's focus remains on developing treatments for health issues such as alcohol use disorder and it holds a portfolio of fifteen patent families in the field of psychedelic-based compounds.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more